Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Posted 2024-06-13, Business Wire Headlines photo

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and... read full story

Ask about this article

Answer for your question of the article will be displayed here ...